ALSO NOTED: ReNeuron confident of trial OK; Valeant licenses Xyrem rights;and much more...

> ReNeuron Group says it is confident that it can gain regulatory approval to start a Phase I stem cell trial of ReN001 after the FDA put a hold on the study on Tuesday. Report

> Valeant Pharmaceuticals has licensed the Canadian rights to Jazz's cataplexy treatment Xyrem. Report

> A group of buyout firms including Texas Pacific have set their sights on a potential offer for Merck KGaA's generic drug unit. Report

> Chelsea Therapeutics is touting the outcome of a European Phase IIb trial of Droxidopa for neurogenic orthostatic hypotension. Release

And Finally… ASCO has touted the development of more targeted cancer therapies as well as a newly approved cervical cancer vaccine as the top advancements in the field for 2006. Sutent, Tykerb, Sprycel and Erbitux have all been held up as examples of effective, targeted cancer drugs. Article

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.